Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06338995 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

Name: A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) — clinical trial record (NCT06338995)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorEli Lilly and Company

Started2024-04-29

View on ClinicalTrials.gov ↗

The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in participants with chronic rhinosinusitis and nasal polyps treated with intranasal corticosteroids. The study will last about 18 months.

Amendment history 2 changes detected by DataLookout

2026-07-08

Trial sites expanded: 194 → 202 locations

2026-04-21

Trial sites expanded: 190 → 194 locations

Trial Details

NCT Number	NCT06338995
Lead Sponsor	Eli Lilly and Company
Conditions	Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Enrollment	510 participants
Start Date	2024-04-29
Primary Completion	2027-05 (estimated)
Study Completion	2028-03 (estimated)
Updated on ClinicalTrials.gov	2026-08-24